Vopratelimab

Cat. No.:	HY-P99382
CAS No.:	2039148-04-2
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response[1].
In Vitro	Vopratelimab (JTX-2011; 0.001-10 μg/mL; 3 d; CD4 T cells) has the activity of activating primary human T cells, driving IFNγ, IL-17a, IL-10, IL-9, GM-CSF, TNFα, and IL-21 secretion[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Vopratelimab (JTX-2011; 0.25-0.3 mg/kg; i.p.; twice a week, for 2 weeks) promotes tumor regression in the Sa1/N murine syngeneic tumor model[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female A/J, Balb/c and C57BL/6 mice with Sa1/N murine syngeneic tumor model[1]
Dosage:	0.25-0.3 mg/kg
Administration:	Intraperitoneal injection; twice a week, for 2 weeks
Result:	Regressed tumor and protected long-term in the Sa1/N murine syngeneic tumor model.

REFERENCES

[1]. Hanson A, et, al. ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. PLoS One. 2020 Sep 24;15(9):e0239595.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA